Eosinophils in human oral squamous carcinoma; Role of prostaglandin D2

Journal of Inflammation (United Kingdom)

Volumn 10, Issue 1, 2013, Pages

  Davoine, Francis ^a   Sim, Adrian ^a   Tang, Charlie ^a   Fisher, Sibina ^a   Ethier, Caroline ^a   Puttagunta, Lakshmi ^a   Wu, Yingqi ^a   McGaw, W Tim ^a   Yu, Donald ^a   Cameron, Lisa ^a   Adamko, Darryl J ^b   Moqbel, Redwan ^c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Eosinophils; HQL 79; Oral squamous carcinoma; Prostaglandin D2; Transmigration

Indexed keywords

4 BENZHYDRYLOXY 1 [3 (1H TETRAZOL 5 YL)PROPYL]PIPERIDINE; ANTINEOPLASTIC AGENT; PROSTAGLANDIN D2; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BASEMENT MEMBRANE; CELL MIGRATION; CELL VIABILITY; CENTRIFUGATION; CONTROLLED STUDY; DEGRANULATION; ENZYME RELEASE; EOSINOPHIL; EXOCYTOSIS; GRANULOCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUTH SQUAMOUS CELL CARCINOMA; PROTEIN FUNCTION; PROTEIN SECRETION;

EID: 84873030029     PISSN: None     EISSN: 14769255     Source Type: Journal    
DOI: 10.1186/1476-9255-10-4     Document Type: Article

References (37)

1. The rise of the phoenix: the expanding role of the eosinophil in health and disease. Adamko DJ, Odemuyiwa SO, Vethanayagam D, Moqbel R, Allergy 2005 60 13 22
2. Eosinophils and human cancer. Samoszuk M, Histol Histopathol 1997 12 807 812
3. Eosinophil-rich squamous carcinoma of the oral cavity: a study of 13 cases and delineation of a possible new microscopic entity. Falconieri G, Luna MA, Pizzolitto S, DeMaglio G, Angione V, Rocco M, Ann Diagn Pathol 2008 12 322 327
4. Significance of eosinophil counting in tumor associated tissue eosinophilia (TATE). Alkhabuli JO, High AS, Oral Oncol 2006 42 849 850
5. Tissue eosinophilic infiltration: a useful marker for assessing stromal invasion, survival and locoregional recurrence in head and neck squamous neoplasia. Alrawi SJ, Tan D, Stoler DL, Dayton M, Anderson GR, Mojica P, Douglas W, Hicks W Jr, Rigual N, Loree T, Cancer J 2005 11 217 225
6. Tumour-associated tissue eosinophilia as a prognostic factor in oral squamous cell carcinomas. Dorta RG, Landman G, Kowalski LP, Lauris JR, Latorre MR, Oliveira DT, Histopathology 2002 41 152 157
7. Prognostic factors for well-differentiated squamous cell carcinoma in the oral cavity with emphasis on immunohistochemical evaluation. Horiuchi K, Mishima K, Ohsawa M, Sugimura M, Aozasa K, J Surg Oncol 1993 53 92 96
8. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, Edelstein D, Soslow RA, Koki AT, Woerner BM, Cancer Res 1999 59 991 994
9. Prostaglandin E2 concentrations in naturally occurring canine cancer. Mohammed SI, Coffman K, Glickman NW, Hayek MG, Waters DJ, Schlittler D, DeNicola DB, Knapp DW, Prostaglandins Leukot Essent Fatty Acids 2001 64 1 4
10. Cyclooxygenase-2 expression in oral squamous cell carcinoma. Pannone G, Bufo P, Caiaffa MF, Serpico R, Lanza A, Lo Muzio L, Rubini C, Staibano S, Petruzzi M, De Benedictis M, Int J Immunopathol Pharmacol 2004 17 273 282
11. Expression of cyclo-oxygenase-2 in human tongue carcinoma and its precursor lesions. Renkonen J, Wolff H, Paavonen T, Virchows Arch 2002 440 594 597
12. Inhibition of cyclooxygenase-2 suppresses invasiveness of oral squamous cell carcinoma cell lines via down-regulation of matrix metalloproteinase-2 and CD44. Kinugasa Y, Hatori M, Ito H, Kurihara Y, Ito D, Nagumo M, Clin Exp Metastasis 2004 21 737 745
13. Inhibition of cyclooxygenase-2 expression. An approach to preventing head and neck cancer. Mestre JR, Chan G, Zhang F, Yang EK, Sacks PG, Boyle JO, Shah JP, Edelstein D, Subbaramaiah K, Dannenberg AJ, Ann N Y Acad Sci 1999 889 62 71
14. The cyclooxygenase 2-selective inhibitor NS398 inhibits proliferation of oral carcinoma cell lines by mechanisms dependent and independent of reduced prostaglandin E2 synthesis. Minter HA, Eveson JW, Huntley S, Elder DJ, Hague A, Clin Cancer Res 2003 9 1885 1897
15. Specific inhibition of cyclooxygenase-2 results in inhibition of proliferation of oral cancer cell lines via suppression of prostaglandin E2 production. Sumitani K, Kamijo R, Toyoshima T, Nakanishi Y, Takizawa K, Hatori M, Nagumo M, J Oral Pathol Med 2001 30 41 47
16. Prostaglandin D2 induces chemotaxis in eosinophils via its receptor CRTH2 and eosinophils may cause severe ocular inflammation in patients with allergic conjunctivitis. Fujishima H, Fukagawa K, Okada N, Takano Y, Tsubota K, Hirai H, Nagata K, Matsumoto K, Saito H, Cornea 2005 24 66 S70
17. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. Hirai H, Tanaka K, Yoshie O, Ogawa K, Kenmotsu K, Takamori Y, Ichimasa M, Sugamura K, Nakamura M, Takano S, Nagata K, J Exp Med 2001 193 255 261
18. Prostaglandin D2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. Monneret G, Gravel S, Diamond M, Rokach J, Powell WS, Blood 2001 98 1942 1948
19. Interleukin-12 inhibits eosinophil degranulation and migration but does not promote eosinophil apoptosis. Davoine F, Ferland C, Chakir J, Lee JE, Adamko DJ, Moqbel R, Laviolette M, Int Arch Allergy Immunol 2006 140 277 284
20. Eotaxin promotes eosinophil transmigration via the activation of the plasminogen-plasmin system. Ferland C, Guilbert M, Davoine F, Flamand N, Chakir J, Laviolette M, J Leukoc Biol 2001 69 772 778
21. Structural and functional characterization of HQL-79, an orally selective inhibitor of human hematopoietic prostaglandin D synthase. Aritake K, Kado Y, Inoue T, Miyano M, Urade Y, J Biol Chem 2006 281 15277 15286
22. Prostaglandin H2 induces the migration of human eosinophils through the chemoattractant receptor homologous molecule of Th2 cells, CRTH2. Schuligoi R, Sedej M, Waldhoer M, Vukoja A, Sturm EM, Lippe IT, Peskar BA, Heinemann A, J Leukoc Biol 2009 85 136 145
23. The induction of eosinophil peroxidase release: improved methods of measurement and stimulation. Adamko DJ, Wu Y, Gleich GJ, Lacy P, Moqbel R, J Immunol Methods 2004 291 101 108
24. The role of eosinophils and eosinophil cationic protein in oral cancer: a review. Pereira MC, Oliveira DT, Kowalski LP, Arch Oral Biol 2011 56 353 358
25. Expression of prostaglandin E2 receptors in oral squamous cell carcinomas and growth inhibitory effects of an EP3 selective antagonist, ONO-AE3-240. Hoshikawa H, Goto R, Mori T, Mitani T, Mori N, Int J Oncol 2009 34 847 852
26. PGE2 production in oral cancer cell lines is COX-2-dependent. Husvik C, Khuu C, Bryne M, Halstensen TS, J Dent Res 2009 88 164 169
27. Administration of interleukin-2 (IL-2) results in increased plasma concentrations of IL-5 and eosinophilia in patients with cancer. van Haelst Pisani C, Kovach JS, Kita H, Leiferman KM, Gleich GJ, Silver JE, Dennin R, Abrams JS, Blood 1991 78 1538 1544
28. In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5. Rivoltini L, Viggiano V, Spinazze S, Santoro A, Colombo MP, Takatsu K, Parmiani G, Int J Cancer 1993 54 8 15
29. Gene expression of interleukin-2 in purified human peripheral blood eosinophils. Bosse M, Audette M, Ferland C, Pelletier G, Chu HW, Dakhama A, Lavigne S, Boulet LP, Laviolette M, Immunology 1996 87 149 154
30. Identification of interleukin-2 in human peripheral blood eosinophils. Levi-Schaffer F, Barkans J, Newman TM, Ying S, Wakelin M, Hohenstein R, Barak V, Lacy P, Kay AB, Moqbel R, Immunology 1996 87 155 161
31. Interleukin-2 induces peroxide production by primed normodense eosinophils of patients with asthma. Conesa A, Tassinari P, Aldrey O, Taylor P, Bianco NE, De Sanctis JB, Allergy Asthma Proc 2003 24 27 33
32. Effects of IFN on human eosinophils in comparison with other cytokines. A novel class of eosinophil activators with delayed onset of action. Valerius T, Repp R, Kalden JR, Platzer E, J Immunol 1990 145 2950 2958
33. Tumor-associated eosinophilia in interleukin-2-treated patients: evidence of toxic eosinophil degranulation on bladder cancer cells. Huland E, Huland H, J Cancer Res Clin Oncol 1992 118 463 467
34. Eosinophils and C4 predict clinical failure of combination immunotherapy with very low dose subcutaneous interleukin-2 and interferon in renal cell carcinoma patients. Moroni M, Porta C, De Amici M, Quaglini S, Cattabiani MA, Buzio C, Haematologica 2000 85 298 303
35. Cytotoxic properties of eosinophil granule major basic protein for tumor cells. Kubo H, Loegering DA, Adolphson CR, Gleich GJ, Int Arch Allergy Immunol 1999 118 426 428
36. Eosinophil granules function extracellularly as receptor-mediated secretory organelles. Neves JS, Perez SA, Spencer LA, Melo RC, Reynolds L, Ghiran I, Mahmudi-Azer S, Odemuyiwa SO, Dvorak AM, Moqbel R, Weller PF, Proc Natl Acad Sci U S A 2008 105 18478 18483
37. Eosinophils: biological properties and role in health and disease. Hogan SP, Rosenberg HF, Moqbel R, Phipps S, Foster PS, Lacy P, Kay AB, Rothenberg ME, Clin Exp Allergy 2008 38 709 750